Dr Martens /£DOCS
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Dr Martens
Dr. Martens, also known as Docs or DMs, is a United Kingdom-based company renowned for its iconic range of footwear, alongside a variety of clothing and accessories. The company, headquartered in Wollaston, Northamptonshire, operates primarily in the footwear manufacturing sector. Established in 1947, Dr. Martens has grown to become a symbol of self-expression and counterculture, distributing its products worldwide under the Dr. Martens brand.
Ticker
£DOCS
Sector
Primary listing
LSE
Employees
2,348
Headquarters
Website
Dr Martens Metrics
BasicAdvanced
£859M
189.26
£0.00
0.23
£0.03
2.88%
Price and volume
Market cap
£859M
Beta
0.23
52-week high
£1.01
52-week low
£0.43
Average daily volume
1.9M
Dividend rate
£0.03
Financial strength
Current ratio
2.591
Quick ratio
1.368
Long term debt to equity
97.107
Total debt to equity
110.289
Dividend payout ratio (TTM)
211.11%
Interest coverage (TTM)
2.01%
Profitability
EBITDA (TTM)
75.7
Gross margin (TTM)
64.97%
Net profit margin (TTM)
0.57%
Operating margin (TTM)
7.71%
Effective tax rate (TTM)
48.86%
Revenue per employee (TTM)
£340,000
Management effectiveness
Return on assets (TTM)
4.12%
Return on equity (TTM)
1.23%
Valuation
Price to earnings (TTM)
189.264
Price to revenue (TTM)
1.081
Price to book
2.34
Price to tangible book (TTM)
9.28
Price to free cash flow (TTM)
4.795
Free cash flow yield (TTM)
20.85%
Free cash flow per share (TTM)
0.185
Dividend yield (TTM)
2.88%
Growth
Revenue change (TTM)
-10.20%
Earnings per share change (TTM)
-93.32%
3-year revenue growth (CAGR)
-4.64%
10-year revenue growth (CAGR)
12.84%
3-year earnings per share growth (CAGR)
-70.44%
10-year earnings per share growth (CAGR)
36.65%
3-year dividend per share growth (CAGR)
-22.60%
What the Analysts think about Dr Martens
Analyst ratings (Buy, Hold, Sell) for Dr Martens stock.
Bulls say / Bears say
Dr Martens projected it would return to profit growth in the current financial year, lifting shares by 17% as CEO Ije Nwokorie shifted strategy to expand into new product categories beyond boots. (Reuters)
By moving 62% of its autumn/winter production to Vietnam and 31% to Laos, Dr Martens will avoid the proposed 46% U.S. tariffs on Vietnamese imports, without increasing retail prices for spring/summer or autumn/winter, supporting margin resilience. (Reuters)
According to its June RNS, the company achieved all four FY25 objectives—returning Americas direct-to-consumer sales to growth in H2, pivoting marketing efforts to focus on product, securing £25m in cost savings, and strengthening the balance sheet—setting up for its FY26 'Levers for Growth' initiative. (ADVFN)
FY25 group revenue dropped by 10% to £787.6m, with profit before tax falling sharply to £8.8m from £93.0m the previous year, highlighting significant declines in both revenue and earnings. (Dr. Martens)
Dr Martens expects foreign exchange headwinds in FY26 to cut about £18m from group revenue and £3m from pretax income based on spot rates at June 2, 2025, putting pressure on near-term earnings. (Research-tree)
The group booked £17.9m in exceptional costs in FY25—mainly from job cuts, store impairments and creating a global technology centre—impacting profit and cash flow. (ADVFN)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
Dr Martens Financial Performance
Revenues and expenses
Dr Martens Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Dr Martens stock?
Dr Martens (DOCS) has a market cap of £859M as of October 14, 2025.
What is the P/E ratio for Dr Martens stock?
The price to earnings (P/E) ratio for Dr Martens (DOCS) stock is 189.26 as of October 14, 2025.
Does Dr Martens stock pay dividends?
Yes, the Dr Martens (DOCS) stock pays dividends to shareholders. As of October 14, 2025, the dividend rate is £0.0255 and the yield is 2.88%. Dr Martens has a payout ratio of 211.11% on a trailing twelve-month basis.
When is the next Dr Martens dividend payment date?
The next Dr Martens (DOCS) dividend payment date is unconfirmed.
What is the beta indicator for Dr Martens ?
Dr Martens (DOCS) has a beta rating of 0.23. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.